The purpose of this study is to find out whether treatment with pasritamig and docetaxelprolongs radiographic progression free survival (rPFS) (the length of time from start oftreatment until disease worsens as determined by scans) when compared to treatment withdocetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; acancer of prostate, a male reproductive gland found below the bladder, that grows despitelow levels of male hormones).
The purpose of this study is to find out whether treatment with pasritamig and docetaxelprolongs radiographic progression free survival (rPFS) (the length of time from start oftreatment until disease worsens as determined by scans) when compared to treatment withdocetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; acancer of prostate, a male reproductive gland found below the bladder, that grows despitelow levels of male hormones).
